NHSGGC : NHS Greater Glasgow and Clyde - Homepage of …



[pic] [pic] [pic]

This bulletin covers aspects of lymphomas and should be of interest to multidisciplinary teams working in this area.

Sections can include:

• Combined Modality Therapies

• Drug & Biological Therapies

• Pathology, Staging, Polymorphisms & Biomarkers

• Prognosis, Survival & Risk Factors

• Radiotherapy & Imaging

• Stem Cell Transplantation

• Supportive Care & Symptom Management

Many of the following articles are available online via the NHS Scotland Knowledge Network. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at knowledge.scot.nhs.uk/

If the article you require is not available via the NHS Scotland Knowledge Network and you would like to request a print copy, please submit your request online at quest.scot.nhs.uk

This bulletin contains a selection of material gathered from a search of the evidence base, and is not intended to be comprehensive. Professional judgment should be exercised when appraising the material. The Library takes no responsibility for the wording, content and accuracy of the information supplied, which has been extracted in good faith from reputable sources. NHSGGC is not responsible for the content of external internet sites.

Compiled by:

Kirsty Coltart

Subject Librarian

Beatson West of Scotland Cancer Centre

0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk

General

Ansell, S.M. (2014). Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology 89,7:771-779.

Bruno Ventre, M., Ferreri, A.J., Gospodarowicz, M., et al. (2014). Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist 19,3:291-298.

Freedman, A. (2014). Follicular lymphoma: 2014 update on diagnosis and management. American Journal of Hematology 89,4:429-436.

Hentrich M. Hoffmann C. Mosthaf F. Muller M. Siehl J. Wyen C. Hensel M. German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA). German AIDS Society (DAIG). (2014). Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNA), in cooperation with the German AIDS Society (DAIG). Annals of Hematology 93,6:913-921.

Messina C. Ferreri AJ. Govi S. Bruno-Ventre M. Gracia Medina EA. Porter D. Radford J. Heo DS. Park HY. Pro B. Jayamohan J. Visco C. Scarfo L. Zucca E. Gospodarowicz M. Christie D. International Extranodal Lymphoma Study Group (I.E.L.S.G.). (2014). Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). British journal of haematology 164,6:834-840.

Moskowitz, A.J., Lunning, M.A. and Horwitz, S.M. (2014). How I treat the peripheral T-cell lymphomas. Blood 123,17:2636-2644.

Zaja, F., Federico, M., Vitolo, U., et al. (2014). Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. Leukemia & lymphoma 55,5:988-998.

Zelenetz, A.D., Gordon, L.I., Wierda, W.G., et al. (2014). Non-Hodgkin's Lymphomas, Version 2.2014. Journal of the National Comprehensive Cancer Network 12,6:916-946.

Combined Modality Therapies

Bersvendsen, H., Kolstad, A., Blystad, A.K., et al. (2014). Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. Acta Oncologica 53,5:680-687.

Briones J. Novelli S. Garcia-Marco JA. Tomas JF. Bernal T. Grande C. Canales MA. Torres A. Moraleda JM. Panizo C. Jarque I. Palmero F. Hernandez M. Gonzalez-Barca E. Lopez D. Caballero D. Grupo Espanol de Linfomas y Trasplante Autologo de Medula Osea (GELTAMO). (2014). Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 99,7:e126.

Glass, B., Hasenkamp, J., Wulf, G., et al. (2014). Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncology 15,7:757-766.

Jiang, L., Li, S.J., Jiang, Y.M., et al. (2014). The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis. Leukemia & lymphoma 55,5:1038-1048.

Metzner, B., Muller, T.H., Gebauer, W., et al. (2014). Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation. Annals of Hematology 93,5:803-810.

Waibel, M., Gregory, G., Shortt, J., et al. (2014). Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. Current opinion in hematology 21,4:297-308.

Drug & Biological Therapies

Advani, A.S., McDonough, S., Coutre, S., et al. (2014). SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British journal of haematology 165,4:504-509.

Chang, J.E., Li, H., Smith, M.R., et al. (2014). Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood 123,11:1665-1673.

de Vos, S., Forero-Torres, A., Ansell, S.M., et al. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of hematology & oncology 7,1:44.

Derenzini, E., Zinzani, P.L. and Cheson, B.D. (2014). Bendamustine: role and evidence in lymphoma therapy, an overview. Leukemia & lymphoma 55,7:1471-1478.

Desai, M., Newberry, K., Ou, Z., et al. (2014). Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Therapeutic Advances in Hematology 5,3:91-101.

Dickinson, M. and Prince, H.M. (2014). Emerging drugs for T-cell lymphoma. Expert Opinion on Emerging Drugs 19,2:201-213.

Eichenauer, D.A., Boll, B. and Diehl, V. (2014). Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert opinion on pharmacotherapy 15,8:1139-1151.

Eichenauer, D.A. and Engert, A. (2014). Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. European journal of haematology 93,1:1-8.

Evens, A.M., Carson, K.R., Kolesar, J., et al. (2014). A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Annals of Oncology 25,7:1449.

Feldman, T., Mato, A.R., Chow, K.F., et al. (2014). Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. British journal of haematology 166,1:77-83.

Ferreri, A.J., Ciceri, F., Brandes, A.A., et al. (2014). MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology 82,15:1370-1373.

Flinn, I.W., Kahl, B.S., Leonard, J.P., et al. (2014). Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123,22:3406-3413.

Flinn, I.W., van der Jagt, R., Kahl, B.S., et al. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123,19:2944-2952.

Ganjoo, K., Hong, F., Horning, S.J., et al. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & lymphoma 55,4:768-772.

Hertzberg, M., Matthews, J.P., Stone, J.M., et al. (2014). A phase III randomized trial of high-dose CEOP+filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial. American Journal of Hematology 89,5:536-541.

Kolstad, A., Laurell, A., Jerkeman, M., et al. (2014). Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 123,19:2953-2959.

Levy, R., Ganjoo, K.N., Leonard, J.P., et al. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology 32,17:1797-1803.

Nabhan, C., Ollberding, N.J., Villines, D., et al. (2014). A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leukemia & lymphoma 55,6:1288-1294.

Ogura, M., Ando, K., Suzuki, T., et al. (2014). A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. British journal of haematology 165,6:768-776.

Ogura, M., Ishida, T., Hatake, K., et al. (2014). Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Journal of Clinical Oncology 32,11:1157-1163.

Ozkan, H.A., Bal, C. and Gulbas, Z. (2014). Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review. European journal of haematology 92,5:390-397.

Palanca-Wessels, M.C. and Press, O.W. (2014). Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123,15:2293-2301.

Rizzieri DA. Johnson JL. Byrd JC. Lozanski G. Blum KA. Powell BL. Shea TC. Nattam S. Hoke E. Cheson BD. Larson RA. Alliance for Clinical Trials In Oncology (ACTION). (2014). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. British journal of haematology 165,1:102-111.

Robak, T. and Robak, E. (2014). Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. Expert opinion on investigational drugs 23,7:911-924.

Ruan, J., Gregory, S.A., Christos, P., et al. (2014). Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma, myeloma & leukemia 14,2:107-113.

Russo, F., Corazzelli, G., Frigeri, F., et al. (2014). A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. British journal of haematology 166,1:118-129.

Salar, A., Avivi, I., Bittner, B., et al. (2014). Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study. Journal of Clinical Oncology 32,17:1782-1791.

Sanchez Ruiz, A.C., de la Cruz-Merino, L. and Provencio Pulla, M. (2014). Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma. Therapeutic Advances in Hematology 5,3:78-90.

Sotomayor, E.M., Young, K.H. and Younes, A. (2014). Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy. Clinical Advances in Hematology & Oncology 12,4 Suppl 10:1-22.

Wang, M., Popplewell, L.L., Collins, R.H.,Jr, et al. (2014). Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. British journal of haematology 165,4:510-518.

Pathology, Staging, Polymorphisms & Biomarkers

Cook, J.R., Goldman, B., Tubbs, R.R., et al. (2014). Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. American Journal of Surgical Pathology 38,4:494-501.

Dunleavy, K. and Wilson, W.H. (2014). Appropriate management of molecular subtypes of diffuse large B-cell lymphoma. Oncology (Williston Park) 28,4:326-334.

Ferreira, A.C., Robaina, M.C., Rezende, L.M., et al. (2014). Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101. Annals of Hematology 93,6:983-993.

Gasparini, C., Celeghini, C., Monasta, L., et al. (2014). NF-B pathways in hematological malignancies. Cellular & Molecular Life Sciences 71,11:2083-2102.

Giannini, C., Dogan, A. and Salomao, D.R. (2014). CNS lymphoma: a practical diagnostic approach. Journal of Neuropathology & Experimental Neurology 73,6:478-494.

Hales, E.C., Taub, J.W. and Matherly, L.H. (2014). New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of -secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cellular signalling 26,1:149-161.

Hatzi, K. and Melnick, A. (2014). Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends in molecular medicine 20,6:343-352.

He, X., Chen, Z., Fu, T., et al. (2014). Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 14,153.

Hsi, E.D., Said, J., Macon, W.R., et al. (2014). Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. American Journal of Surgical Pathology 38,6:768-775.

Lossos, C., Bayraktar, S., Weinzierl, E., et al. (2014). LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. British journal of haematology 165,5:640-648.

Sakata-Yanagimoto, M., Enami, T., Yokoyama, Y., et al. (2014). Disease-specific mutations in mature lymphoid neoplasms: recent advances. Cancer Science 105,6:623-629.

Shaw, A., Iyer, V., Rooney, N., et al. (2014). Diagnosis of primary cerebral lymphomas: possible value of PCR testing in equivocal cases requiring rebiopsy. British journal of neurosurgery 28,2:214-219.

Sovani, V., Harvey, C., Haynes, A.P., et al. (2014). Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings. Journal of clinical pathology 67,5:389-395.

Zhou, C., Cui, S., Zhou, R., et al. (2014). Association between interleukin-4 -590C > T polymorphism and non-Hodgkin's lymphoma risk. Tumour Biology 35,4:3041-3045.

Prognosis, Survival & Risk Factors

Cella, L., Liuzzi, R., D'Avino, V., et al. (2014). Pulmonary damage in Hodgkin's lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury. Acta Oncologica 53,5:613-619.

Cohen, J.B., Geyer, S.M., Lozanski, G., et al. (2014). Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer 120,11:1677-1685.

Daniels, L.A., Krol, A.D., de Graaf, M.A., et al. (2014). Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: phase II study of indication and acceptance+. Annals of Oncology 25,6:1198-1203.

Guitart, J., Deonizio, J., Bloom, T., et al. (2014). High incidence of gastrointestinal tract disorders and autoimmunity in primary cutaneous marginal zone B-cell lymphomas. JAMA Dermatology 150,4:412-418.

Gurney, J.G., Kaste, S.C., Liu, W., et al. (2014). Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatric Blood & Cancer 61,7:1270-1276.

Hoster, E., Klapper, W., Hermine, O., et al. (2014). Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. Journal of Clinical Oncology 32,13:1338-1346.

Jochem, C., Leitzmann, M.F., Keimling, M., et al. (2014). Physical activity in relation to risk of hematologic cancers: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers & Prevention 23,5:833-846.

Maurer, M.J., Ghesquieres, H., Jais, J.P., et al. (2014). Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology 32,10:1066-1073.

Radiotherapy & Imaging

Adams, H.J., Kwee, T.C., de Keizer, B., et al. (2014). Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary?. Annals of Oncology 25,5:921-927.

El-Galaly, T.C., Mylam, K.J., Bogsted, M., et al. (2014). Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. American Journal of Hematology 89,6:575-580.

Gallamini, A., Barrington, S.F., Biggi, A., et al. (2014). The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99,6:1107-1113.

Gallamini, A. and Borra, A. (2014). Role of PET in Lymphoma. Current Treatment Options in Oncology 15,2:248-261.

Illidge, T., Specht, L., Yahalom, J., et al. (2014). Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. International journal of radiation oncology, biology, physics 89,1:49-58.

Kobe, C., Kuhnert, G., Kahraman, D., et al. (2014). Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage hodgkin lymphoma. Journal of Clinical Oncology 32,17:1776-1781.

Kostakoglu, L. and Cheson, B.D. (2014). Current role of FDG PET/CT in lymphoma. European Journal of Nuclear Medicine & Molecular Imaging 41,5:1004-1027.

Martelli, M., Ceriani, L., Zucca, E., et al. (2014). [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. Journal of Clinical Oncology 32,17:1769-1775.

Oki, Y., Chuang, H., Chasen, B., et al. (2014). The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British journal of haematology 165,1:112-116.

Picardi, M., Pugliese, N., Cirillo, M., et al. (2014). Advanced-stage Hodgkin Lymphoma: US/Chest Radiography for Detection of Relapse in Patients in First Complete Remission-A Randomized Trial of Routine Surveillance Imaging Procedures. Radiology 272,1:262-274.

Raemaekers, J.M., Andre, M.P., Federico, M., et al. (2014). Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Journal of Clinical Oncology 32,12:1188-1194.

Weiler-Sagie, M., Kagna, O., Dann, E.J., et al. (2014). Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT. European Journal of Nuclear Medicine & Molecular Imaging 41,6:1133-1140.

Yahalom, J. (2014). Radiotherapy of follicular lymphoma: updated role and new rules. Current Treatment Options in Oncology 15,2:262-268

Zacher, J., Kasenda, B., Engert, A., et al. (2014). The role of additional radiotherapy for primary central nervous system lymphoma. Cochrane Database of Systematic Reviewsz 6,009211.

Special Populations

Held, G., Murawski, N., Ziepert, M., et al. (2014). Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. Journal of Clinical Oncology 32,11:1112-1118.

Huynh-Le, M.P., Walker, A.J., Kominers, S.D., et al. (2014). Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma. Pediatric Blood & Cancer 61,7:1210-1214.

Percival, M.E., Hoppe, R.T. and Advani, R.H. (2014). Bulky mediastinal classical Hodgkin lymphoma in young women. Oncology (Williston Park) 28,3:253-256.

Place, A.E., Frederick, N.N. and Sallan, S.E. (2014). Therapeutic approaches to haematological malignancies in adolescents and young adults. British journal of haematology 164,1:3-14.

Samochatova, E.V., Maschan, A.A., Shelikhova, L.N., et al. (2014). Therapy of Advanced-stage Mature B-cell Lymphoma and Leukemia in Children and Adolescents With Rituximab and Reduced Intensity Induction Chemotherapy (B-NHL 2004M Protocol): The Results of a Multicenter Study. Journal of Pediatric Hematology/Oncology 36,5:395-401.

Terezakis, S.A., Metzger, M.L., Hodgson, D.C., et al. (2014). ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatric Blood & Cancer 61,7:1305-1312.

Vitolo, U., Chiappella, A., Franceschetti, S., et al. (2014). Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncology 15,7:730-737.

Supportive Care & Symptom Management

Felbel, S., Meerpohl, J.J., Monsef, I., et al. (2014). Yoga in addition to standard care for patients with haematological malignancies. Cochrane Database of Systematic Reviews 6,010146.

Langeberg, W.J., Siozon, C.C., Page, J.H., et al. (2014). Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Supportive Care in Cancer 22,8:2167-2175.

Lee, S.Y., Kurita, N., Yokoyama, Y., et al. (2014). Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Supportive Care in Cancer 22,5:1385-1390.

Morrison, V.A. (2014). Infections in patients with leukemia and lymphoma. Cancer Treatment & Research 161,319-349.

Transplantation

Harrison, S.J., Hsu, A.K., Neeson, P., et al. (2014). Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leukemia & lymphoma 55,5:1053-1060.

Kharfan-Dabaja, M.A., Hamadani, M., Sibai, H., et al. (2014). Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!. Bone marrow transplantation 49,5:599-606.

Kim, J.H., Stein, A., Tsai, N., et al. (2014). Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. International journal of radiation oncology, biology, physics 89,1:75-81.

Sureda, A., Domenech, E., Schmitz, N., et al. (2014). The Role of Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma. Current Treatment Options in Oncology 15,2:238-247.

Please note that the journal articles you are accessing are subject to the terms and conditions imposed by the publisher, so there will be a limit on the number of articles an individual may download or print from a single issue of a journal. You can consult your local NHSGGC library with any queries.

If you have any questions regarding this or any other library services please contact Library staff – contact details are at the beginning of the bulletin.

Sources used for this bulletin:

OVID databases

-----------------------

Lymphomas

July 2014

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download